# Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)

> **NCT06305286** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Chicago** · enrollment: 70 (estimated)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy

## Key facts

- **NCT ID:** NCT06305286
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-04
- **Primary completion:** 2029-03
- **Final completion:** 2029-03
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06305286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06305286, "Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06305286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*